Company Profile
Geron Stock Price, News & Analysis
- Ticker:
- GERN
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.57 USD (-3.68%)
Close
Last updated: August 6, 2026
751M USD
Market cap
Why the stock is moving
Following the latest company update, “Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights”, GERN closed up 21.6% at $1.63 on Aug 5, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Telomerase-Targeted Hematology Company
Geron is a commercial-stage biopharmaceutical company focused on blood cancers. Its scientific and commercial strategy is built around inhibiting telomerase, an enzyme involved in the continued proliferation of malignant cells.
RYTELO in Lower-Risk MDS
RYTELO, or imetelstat, is a first-in-class oligonucleotide telomerase inhibitor approved in the United States and European Union for defined adults with transfusion-dependent anemia caused by lower-risk myelodysplastic syndromes. The therapy is administered by intravenous infusion every four weeks.
Differentiated Clinical Profile
RYTELO is intended for patients who have not responded to, have lost response to or are ineligible for erythropoiesis-stimulating therapy. Evidence from the Phase 3 IMerge study supports its ability to produce periods of red-blood-cell transfusion independence, making reduction of transfusion burden central to its clinical value proposition.
Commercialization Footprint
Geron directly commercializes RYTELO in the United States and is assessing how best to commercialize the product in Europe while preserving the economics and pricing integrity of the broader franchise.
Future catalysts
Geron's catalysts are RYTELO rollout in lower-risk MDS and any commercial step that proves the launch is more than just a one-time approval. The market wants to see the product turn into a durable franchise.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Geron (GERN)?
Geron (GERN) most recently closed at 1.57 USD, a -3.68% move versus the previous session.
What is the market cap of Geron (GERN)?
Geron currently has a market capitalization of 751M USD on BioPharmSignal.
What does Geron do?
Telomerase-Targeted Hematology Company Geron is a commercial-stage biopharmaceutical company focused on blood cancers. Its scientific and commercial strategy is built around inhibiting telomerase, an enzyme involved in the continued proliferation of malignant cells. RYTELO in Lower-Risk MDS RYTELO, or imetelstat, is a first-in-class oligonucleotide...
On which exchange is GERN stock listed?
Geron (GERN) is associated with NASDAQ, United States, Biopharma.
What is imetelstat?
RYTELO in Lower-Risk MDS RYTELO, or imetelstat, is a first-in-class oligonucleotide telomerase inhibitor approved in the United States and European Union for defined adults with transfusion-dependent anemia caused by lower-risk myelodysplastic syndromes.
Which conditions is Geron targeting with imetelstat?
Geron is associated with cancer therapeutics, hematology based on its company overview and current catalyst commentary.
How does Geron describe recent progress with imetelstat?
Geron's catalysts are RYTELO rollout in lower-risk MDS and any commercial step that proves the launch is more than just a one-time approval. The market wants to see the product turn into a durable franchise.
What is Telomerase-Targeted?
Telomerase-Targeted Hematology Company Geron is a commercial-stage biopharmaceutical company focused on blood cancers.